Transforming science into medicine

‘We are committed to developing novel compounds in oncology that will deliver life-changing innovations for patients.’

Philip Serlin, CEO

Press Release August 19, 2020

BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned…

Upcoming Event September 24, 2020

Annual General Meeting of Shareholders 2020

Pipeline

Motixafortide (BL-8040)

Stem Cell Mobilization

Motixafortide (BL-8040) blocks the interaction between CXCL12 and CXCR4 leading to robust mobilization of stem cells to the periperal blood for collection and transplant.

Pipeline

Motixafortide (BL-8040)

Acute Myeloid Leukemia (AML)

Motixafortide (BL-8040) mobilizes leukemic cells from bone marrow’s protective niche resulting in sensitization to anti-cancer treatment; induction of apoptosis.

Pipeline

Motixafortide (BL-8040)

Solid Tumors

Motixafortide (BL-8040) mobilizes immune cells to peripheral blood circulation, leading to Increase in immune cell infiltration into tumors and reduction in immunosuppression in tumor microenvironment.

Pipeline

AGI-134

Solid Tumors

AGI-134 is a universal drug that evokes a vaccine effect via a unique, hyper-acute, multi-arm mechanism that targets patient-specific neoantigens

Partnering

In-licensing
BioLineRx is committed to the identification, in-licensing and systematic development of promising therapeutic candidates. Through this strategy, BioLineRx is building a pipeline of powerful technologies in oncology.

Out-licensing
BioLineRx seeks to collaborate with leading global pharmaceutical companies with a proven track record in clinical experience, for completion of the final phases of the clinical trials, and commercial capabilities, to successfully bring our innovative developments to market. We believe that this is the way to combine our drug development expertise with your commercial development capabilities.

Investors

Delayed up to 30 minutes - See terms
Delayed up to 30 minutes - See terms